The Final Answer For HIV? How Effective Is Sofosbuvir/Ledispasvir For People With HIV And HCV?
In a couple of days, the annual celebration of World AIDS day will once again be celebrated. It was in line with this fact that UN has called for urgent series of actions which is necessary in order to help and protect HIV patients across the globe.
In the recently concluded 2016 AASLD Liver meeting this month, the pooled analysis has shown that the sofosbuvir/ledipasvir also known as Harvoni co-formulation which is widely used in real-world clinical practice has produced good sustained virological response rates , which is similar to those seen in clinical trials for HIV-positive people with hepatitis C co-infection.
Sofosbuvir/Ledispasvir Being Used For HIV Patients, How Effective Was It?
It was found that HIV-positive people who have co infection with hepatitis C virus (HCV) experience more rapid liver disease progression on average and did not respond as well as HIV-negative people to interferon-based hepatitis C treatment. As per Aids Map, Susanna Naggie of Duke University and colleagues was found to have compared the efficacy of the sofosbuvir/ledipasvir single tablet regimen for people with HIV/HCV co-infection with HCV genotype 1 in clinical trials against its effectiveness in real-world cohorts.
On the other hand, according to Info Hep, it was found that new and direct-acting antivirals (DAAs) used in interferon-free regimens have made treatment simpler, better tolerated and much more effective. Clinical trials showed that DAAs work as well for HIV-positive as for HIV-negative people with hepatitis C. However, scientists have highly emphasized the fact that despite the study findings, they still need to be aware of potential drug-drug interactions with antiretrovirals.
Ultimately, the researchers of the study concludes that sustained virological response rates were high across all populations including populations with traditional negative predictors such as black race, cirrhosis, and treatment-experienced patients. Accordingly, experts have added that the results have coincided with the recent EASL guidelines and AASLD/IDSA guidelines, which recommend sofosbuvir/ledipasvir for people with HIV/HCV co-infection.
Can This Be The Answer To HIV? Authorities From China To Approve The 1st Ever Long-Acting Cure For HIV
With The Rising Number Of HIV Cases, Can This So-Called Groundbreaking HIV Injection Be Finally Considered As 'The Cure' That Everyone’s Been Waiting For?
New HIV Vaccine Will Launch Trial In South Africa
The vaccine to be used is based on a trial in Thailand in 2009. South Africa has at least 6.8 million cases of HIV, so if the trial is successful, it could dramatically change the course of the pandemic.
The Double Jeopardy Effect: African Members Of The LGBTQ Community That Are HIV Positive Are Being Denied Of HIV Aid
With Africa Known To Be The Region Where HIV Is Most Prevalent, Members Of The LGBTQ Community Who Are HIV Positive Are Being Denied Of Having An Access To Health Care, What Can These Oppressions Mean?
MORE IN ITECHPOST
Alcatel Launches A 'Party-Themed' Midrange Smartphone
Spotted at the 2017 MWC is the Alcatel A5 LED (aka Disco Phone) that features three changeable back accessories with pulsing lights and pumping bass.
Apitope's Peptide Vaccine Finally Sheds Light To Multiple Sclerosis; Details Inside
With the continuous efforts to eradicate Multiple Sclerosis, how significant is Apitope's peptide vaccine for the said auto-immune disease? Could this vaccine be the advent of new medications to treat one of the diseases that has already affected millions of lives? Find out what experts have to say
Lazy Bear Games' 'Graveyard Keeper' Released First Trailer
Check out the amazing graveyard simulator entitled Graveyard Keeper.